Latest News - Allergan

Monday, October 16, 2017 | Corporate Lawsuits, Allergan

Allergan Shares Slip As Judge Invalidates Patent on Top Selling Eye Drop

A federal judge struck down patents protecting one of Allergan’s top-selling drugs, sending shares in the company down nearly 5 percent, according to a report in the Financial Times. The Texa…

Read the full story

Wednesday, October 04, 2017 | Patents, Allergan

U.S. House Committee Launches Probe of Allergan Patent Deal

A U.S. House of Representatives committee launched a probe into drugmaker Allergan's deal to transfer some of its patents to a Native American tribe to shield them from review, according to a repo…

Read the full story

Monday, October 02, 2017 | Corporate Lawsuits, Dry Eye, Allergan, Shire

Shire Alleges Allergan Blocked Drug From Medicare Contracts

Shire filed an antitrust suit against Allergan alleging Allergan’s contracts with Medicare Part D drug plans for its Restasis eye drops effectively blocked access to Shire’s rival drug, ac…

Read the full story

Tuesday, September 26, 2017 | Earnings & Financials, Allergan

Allergan Authorizes New $2 Billion Share Repurchase Program

Allergan announced that the company's board of directors has authorized a new $2 billion share repurchase program, and has affirmed its commitment to increasing its regular quarterly cash dividend…

Read the full story

Monday, September 18, 2017 | Corporate Lawsuits, Patents, Allergan

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Allergan caused a lot of hand-wringing in the biotech community and excitement among patent lawyers, when the drugmaker announced it would transfer patents for Restasis, Allergan's longstandi…

Read the full story

Friday, September 08, 2017 | Partnerships, Allergan

Allergan Partners With Indian Tribe to Protect Restasis Drug Patents

In an unusual strategy to protect Restasis from generic competition, Allergan announced that is it has sold the drug's patents to an Indian tribe in upstate New York. Allergan and the Saint Reg…

Read the full story

Friday, September 08, 2017 | Corporate Lawsuits, Allergan

Allergan Files Suits Against Imprimis Pharmaceuticals, Prescriber's Choice, and Sincerus Florida

Allergan USA has filed lawsuits against Imprimis Pharmaceuticals, Prescriber's Choice, and Sincerus Florida, alleging that those companies are unlawfully manufacturing and selling unapproved new d…

Read the full story

Monday, August 28, 2017 | Miscellaneous, Allergan

The Allergan Foundation to Donate $100,000 to Support Hurricane Harvey Relief Efforts

Allergan announced that The Allergan Foundation will donate $100,000 to help victims of Hurricane Harvey. The Allergan Foundation donation will be made to the American Red Cross, which has mobilized i…

Read the full story

Sunday, July 02, 2017 | Corporate Lawsuits, Allergan

Allergan Settles Whistle-Blower Lawsuit

Allergan settled a whistle-blower lawsuit brought by two Philadelphia-area ophthalmologists who alleged the company provided paid speaking engagements, free business consulting, and other services as …

Read the full story

Thursday, May 11, 2017 | Acquisitions/Mergers, Allergan

Read My Lips, Allergan CEO Tells M&A-Craving Analysts: Don't Expect a Megamerger From Us

Anyone who tuned into Allergan’s Q1 earnings call hoping for signs of big M&A to come likely left disappointed. CEO Brent Saunders, as he has repeatedly over the past year, emphasized Allerg…

Read the full story

Tuesday, April 25, 2017 | FDA Approval/Clearance, Allergan

Allergan Granted Marketing Authorization by the FDA for TrueTear Intranasal Neurostimulating Device

Allergan announced that it has been granted marketing authorization from the FDA for TrueTear Intranasal Tear Neurostimulator, the first and only FDA-cleared device developed to temporarily increase t…

Read the full story

Wednesday, April 19, 2017 | Corporate Lawsuits, Allergan

Allergan, Argentum Settle Patent Dispute Over Restasis

U.S. generic drug company Argentum Pharmaceuticals LLC said on Tuesday it had reached an agreement with Allergan Plc that settles a patent dispute over the generic version of Allergan's eye drug, …

Read the full story

Wednesday, March 29, 2017 | Earnings & Financials, Allergan

Allergan's CEO Pay Plummets by 80%

After a 2016 that hit some bumps financially -- and one that didn’t feature the Pfizer-Allergan merger the companies had planned on -- Allergan CEO Brent Saunders’ pay is down. Way, way do…

Read the full story

Wednesday, March 22, 2017 | Product Releases, Allergan

Allergan Announces Availability of Restasis Multidose (Cyclosporine Ophthalmic Emulsion) 0.05%

Allergan announced the availability of Restasis Multidose, the first and only FDA-approved preservative-free, prescription eye drop in the United States to be available in a multidose bottle. Previous…

Read the full story

Thursday, March 16, 2017 | Blindness, Partnerships, Allergan, Prevent Blindness

Prevent Blindness and Allergan Work Together Through 'See America' to Promote Healthy Vision

Prevent Blindness, the nation’s oldest volunteer eye health and safety group, and Allergan, a global leader in eye care for nearly 70 years, have embarked on a joint effort to promote healthy vi…

Read the full story
Load More